1. New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer 
Noel W. Clarke 
European Urology Supplements 
Volume 5, Issue 17, Pages (October 2006)
DOI: /j.eursup
Copyright © 2006 European Association of Urology Terms and Conditions

2. Fig. 1
Treatment of prostate cancer metastases with bisphosphonates [7–13].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

3. Fig. 2
Zoledronic acid consistently reduces all types of SREs (24 mo). SRE=skeletal-related event; HCM=hypercalcaemia of malignancy. Data from Saad et al. [7].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

4. Fig. 3
Prostate cancer: multiple event analysis by study period [15]. SRE=skeletal-related event. Data from Saad et al. [7,11].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

5. Fig. 4
Prostate cancer: reduction of SRE risk by zoledronic acid, by SRE history. SRE=skeletal-related event. Data from Saad et al. [7].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

6. Fig. 5
Zoledronic acid has a greater efficacy (per primary end point) in patients with no pain at baseline. SRE=Skeletal-related event. Data from Eastham et al. [18].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

7. Fig. 6
Zoledronic acid for the prevention of bone metastases in patients with solid tumours. Adapted with permission from Mystakidou et al. [28].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions